Prostate News and Research

RSS

New promising detection technology identifies cancer cells early

Yesterday's Wall Street Journal (March 1) published a lead article on page D1 entitled "Researchers Create Better Ways To Spot Cancer Cells", which described the research by Dr. Edward R. Flynn, of Senior Scientific LLC. The article was authored by Shirley S. Wang.

4 Mar 2011

How cancer impacts patients and their partners

Katarina Sjövall has studied partners of individuals with colorectal cancer, lung cancer, breast cancer or prostate cancer. The study shows that the number of diagnosed diseases among partners increased by 25 per cent after the cancer diagnosis.

4 Mar 2011

New, inexpensive method to accurately differentiate between benign and malignant breast tumors

Recent research by doctoral student Sevan Goenezen holds the promise of becoming a powerful new weapon in the fight against breast cancer. His complex computational research has led to a fast, inexpensive new method for using ultrasound and advanced algorithms to differentiate between benign and malignant tumors with a high degree of accuracy.

4 Mar 2011

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces its featured products at the European Society of Radiology's annual meeting being held in Vienna, Austria from March 3 - 7, 2011.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

Night shift work may reduce risk of skin cancer in women

Melatonin is known to have cancer-protective properties, and shift work can induce desynchrony of the circadian system, reducing melatonin production. Shift work has been thought to have important health impacts, with evidence linking shift work to an increased risk of several cancers including breast, endometrial, prostate, and colorectal, and non-Hodgkin lymphoma.

2 Mar 2011

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers the same or better results than minimally invasive laparoscopic procedures for treating kidney disease, and can potentially help more patients because it is not as difficult for surgeons to learn, according to a new study led by Henry Ford Hospital specialists.

2 Mar 2011

Robotic surgery offers favourable outcomes in patients with kidney disease

2 Mar 2011

Market demands shape health sector growth

The Wall Street Journal reports on how a string of recent acquisitions are being spurred by an increased demand for outpatient facilities and senior care. However, The Washington Post reports that some specific facilities — those that are doctor-owned, for instance — are sparking criticism.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Sudden cessation of smoking may be symptom of lung cancer

Many longtime smokers quit spontaneously with little effort shortly before their lung cancer is diagnosed, leading some researchers to speculate that sudden cessation may be a symptom of lung cancer.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

As a world leader in the advancement of the detection and treatment of prostate cancer, the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center is the first medical facility in the Northeast to install ei-Nav|Artemis™, an innovative image guidance and navigation system for prostate biopsy that is manufactured by Eigen.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Roundup: In Ariz., Senate panel takes steps to end Medicaid; Mass. Gov. starts sales pitch for payment reform

A Republican proposal to retain solvency in a key state health care fund is making headway at the Capitol, despite the tumultuous ride reform has taken this session. The fund — which supports MinnesotaCare, a state-sponsored program for about 140,000 "working poor" residents — is set to run a $150 million deficit by 2013.

25 Feb 2011

Variation in PSA levels does not predict prostate cancer, may lead to unnecessary biopsies

Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

25 Feb 2011

Australia’s top scientist takes on top job

Today, the man who is known for one of Australia’s greatest medical achievements – the development of a cervical cancer vaccine – has been appointed as Chief Executive Officer of the Translational Research Institute (TRI) in Brisbane, Queensland.

23 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Prostate News and Research

New promising detection technology identifies cancer cells early

How cancer impacts patients and their partners

New, inexpensive method to accurately differentiate between benign and malignant breast tumors

iCAD to showcase its cancer diagnostic imaging products at ECR annual meeting

U-M scientists identify potential target to treat aggressive prostate cancer

Night shift work may reduce risk of skin cancer in women

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers favourable outcomes in patients with kidney disease

Market demands shape health sector growth

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

Sudden cessation of smoking may be symptom of lung cancer

New personalized therapy fools cancer cells into killing themselves

TCD announces first patient treated in its TCD-717 Phase I trial

Eigen ei-Nav|Artemis system for prostate biopsy installed at Smilow Comprehensive Prostate Cancer Center

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Roundup: In Ariz., Senate panel takes steps to end Medicaid; Mass. Gov. starts sales pitch for payment reform

Variation in PSA levels does not predict prostate cancer, may lead to unnecessary biopsies

Australia’s top scientist takes on top job

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News